vs
Postal Realty Trust, Inc.（PSTL）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是Postal Realty Trust, Inc.的1.2倍（$30.3M vs $26.0M），Postal Realty Trust, Inc.净利率更高（17.9% vs -221.3%，领先239.2%），REGENXBIO Inc.同比增速更快（43.0% vs 21.7%），Postal Realty Trust, Inc.自由现金流更多（$37.6M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 22.6%）
Postal Realty Trust, Inc.是一家专业房地产投资信托基金，主要收购、持有和管理租给美国邮政服务的物业，资产组合覆盖美国各地的最后一公里邮政设施、分拣中心及零售邮政网点，为美国邮政及包裹配送基础设施提供支持。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
PSTL vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.2倍
$26.0M
营收增速更快
RGNX
高出21.3%
21.7%
净利率更高
PSTL
高出239.2%
-221.3%
自由现金流更多
PSTL
多$90.4M
$-52.8M
两年增速更快
RGNX
近两年复合增速
22.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $26.0M | $30.3M |
| 净利润 | $4.6M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 39.2% | -190.0% |
| 净利率 | 17.9% | -221.3% |
| 营收同比 | 21.7% | 43.0% |
| 净利润同比 | 3.1% | -31.2% |
| 每股收益（稀释后） | $0.16 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PSTLRGNX
| Q4 25 | $26.0M | $30.3M | ||
| Q3 25 | $24.3M | $29.7M | ||
| Q2 25 | $23.4M | $21.4M | ||
| Q1 25 | $22.1M | $89.0M | ||
| Q4 24 | $21.4M | $21.2M | ||
| Q3 24 | $19.7M | $24.2M | ||
| Q2 24 | $18.1M | $22.3M | ||
| Q1 24 | $17.3M | $15.6M |
净利润PSTLRGNX
| Q4 25 | $4.6M | $-67.1M | ||
| Q3 25 | $3.8M | $-61.9M | ||
| Q2 25 | $3.6M | $-70.9M | ||
| Q1 25 | $2.1M | $6.1M | ||
| Q4 24 | $4.5M | $-51.2M | ||
| Q3 24 | $1.1M | $-59.6M | ||
| Q2 24 | $817.0K | $-53.0M | ||
| Q1 24 | $206.0K | $-63.3M |
毛利率PSTLRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率PSTLRGNX
| Q4 25 | 39.2% | -190.0% | ||
| Q3 25 | 37.6% | -176.3% | ||
| Q2 25 | 37.3% | -296.3% | ||
| Q1 25 | 28.4% | 13.6% | ||
| Q4 24 | 43.2% | -242.1% | ||
| Q3 24 | 24.3% | -256.6% | ||
| Q2 24 | 22.8% | -251.3% | ||
| Q1 24 | 17.6% | -408.8% |
净利率PSTLRGNX
| Q4 25 | 17.9% | -221.3% | ||
| Q3 25 | 15.7% | -208.3% | ||
| Q2 25 | 15.5% | -331.8% | ||
| Q1 25 | 9.4% | 6.8% | ||
| Q4 24 | 21.1% | -241.3% | ||
| Q3 24 | 5.4% | -246.3% | ||
| Q2 24 | 4.5% | -237.7% | ||
| Q1 24 | 1.2% | -405.4% |
每股收益（稀释后）PSTLRGNX
| Q4 25 | $0.16 | $-1.30 | ||
| Q3 25 | $0.13 | $-1.20 | ||
| Q2 25 | $0.12 | $-1.38 | ||
| Q1 25 | $0.06 | $0.12 | ||
| Q4 24 | $0.17 | $-0.99 | ||
| Q3 24 | $0.03 | $-1.17 | ||
| Q2 24 | $0.02 | $-1.05 | ||
| Q1 24 | $-0.01 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.5M | $230.1M |
| 总债务越低越好 | $361.1M | — |
| 股东权益账面价值 | $285.2M | $102.7M |
| 总资产 | $759.1M | $453.0M |
| 负债/权益比越低杠杆越低 | 1.27× | — |
8季度趋势，按日历期对齐
现金及短期投资PSTLRGNX
| Q4 25 | $1.5M | $230.1M | ||
| Q3 25 | $1.9M | $274.2M | ||
| Q2 25 | $1.1M | $323.3M | ||
| Q1 25 | $639.0K | $267.9M | ||
| Q4 24 | $1.8M | $234.7M | ||
| Q3 24 | $970.0K | $255.5M | ||
| Q2 24 | $1.7M | $290.4M | ||
| Q1 24 | $1.9M | $338.7M |
总债务PSTLRGNX
| Q4 25 | $361.1M | — | ||
| Q3 25 | $347.0M | — | ||
| Q2 25 | $328.8M | — | ||
| Q1 25 | $306.7M | — | ||
| Q4 24 | $296.7M | — | ||
| Q3 24 | $277.0M | — | ||
| Q2 24 | $273.7M | — | ||
| Q1 24 | $247.6M | — |
股东权益PSTLRGNX
| Q4 25 | $285.2M | $102.7M | ||
| Q3 25 | $273.9M | $161.5M | ||
| Q2 25 | $250.8M | $213.7M | ||
| Q1 25 | $245.5M | $274.2M | ||
| Q4 24 | $251.3M | $259.7M | ||
| Q3 24 | $245.6M | $301.4M | ||
| Q2 24 | $245.5M | $348.3M | ||
| Q1 24 | $248.1M | $390.7M |
总资产PSTLRGNX
| Q4 25 | $759.1M | $453.0M | ||
| Q3 25 | $735.2M | $525.2M | ||
| Q2 25 | $689.8M | $581.0M | ||
| Q1 25 | $654.0M | $490.9M | ||
| Q4 24 | $646.8M | $466.0M | ||
| Q3 24 | $615.1M | $519.1M | ||
| Q2 24 | $608.2M | $569.4M | ||
| Q1 24 | $584.1M | $629.2M |
负债/权益比PSTLRGNX
| Q4 25 | 1.27× | — | ||
| Q3 25 | 1.27× | — | ||
| Q2 25 | 1.31× | — | ||
| Q1 25 | 1.25× | — | ||
| Q4 24 | 1.18× | — | ||
| Q3 24 | 1.13× | — | ||
| Q2 24 | 1.11× | — | ||
| Q1 24 | 1.00× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $44.5M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $37.6M | $-52.8M |
| 自由现金流率自由现金流/营收 | 144.5% | -174.0% |
| 资本支出强度资本支出/营收 | 26.7% | 1.7% |
| 现金转化率经营现金流/净利润 | 9.59× | — |
| 过去12个月自由现金流最近4个季度 | $65.6M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流PSTLRGNX
| Q4 25 | $44.5M | $-52.3M | ||
| Q3 25 | $10.9M | $-56.0M | ||
| Q2 25 | $11.4M | $-49.3M | ||
| Q1 25 | $10.8M | $33.6M | ||
| Q4 24 | $33.5M | $-31.6M | ||
| Q3 24 | $8.0M | $-40.5M | ||
| Q2 24 | $9.9M | $-45.5M | ||
| Q1 24 | $6.4M | $-55.5M |
自由现金流PSTLRGNX
| Q4 25 | $37.6M | $-52.8M | ||
| Q3 25 | $8.8M | $-56.5M | ||
| Q2 25 | $9.1M | $-49.7M | ||
| Q1 25 | $10.2M | $32.6M | ||
| Q4 24 | $30.7M | $-32.7M | ||
| Q3 24 | $7.4M | $-40.9M | ||
| Q2 24 | $8.9M | $-46.0M | ||
| Q1 24 | $5.8M | $-56.0M |
自由现金流率PSTLRGNX
| Q4 25 | 144.5% | -174.0% | ||
| Q3 25 | 36.1% | -189.9% | ||
| Q2 25 | 38.8% | -232.8% | ||
| Q1 25 | 45.9% | 36.6% | ||
| Q4 24 | 143.8% | -154.2% | ||
| Q3 24 | 37.6% | -168.9% | ||
| Q2 24 | 49.4% | -206.2% | ||
| Q1 24 | 33.6% | -358.5% |
资本支出强度PSTLRGNX
| Q4 25 | 26.7% | 1.7% | ||
| Q3 25 | 8.9% | 1.7% | ||
| Q2 25 | 10.1% | 1.8% | ||
| Q1 25 | 3.0% | 1.2% | ||
| Q4 24 | 13.0% | 5.1% | ||
| Q3 24 | 3.2% | 1.3% | ||
| Q2 24 | 5.4% | 2.1% | ||
| Q1 24 | 3.5% | 3.6% |
现金转化率PSTLRGNX
| Q4 25 | 9.59× | — | ||
| Q3 25 | 2.87× | — | ||
| Q2 25 | 3.16× | — | ||
| Q1 25 | 5.20× | 5.53× | ||
| Q4 24 | 7.44× | — | ||
| Q3 24 | 7.48× | — | ||
| Q2 24 | 12.10× | — | ||
| Q1 24 | 31.07× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PSTL
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
